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Abstract 
Background: Rare tonsillar granulomas may be caused for example by infections, malignancies or sarcoidosis. 
Granulomas also occur in inborn errors of immunity (IEI) such as common variable immunodeficiency (CVID) 
with B cell maturation defects and hypogammaglobulinemia. CVID shares various features with sarcoidosis and 
drug-induced secondary hypogammaglobulinemia; careful consideration of differential diagnosis between these 
conditions is warranted.
Case presentation: A 29-year-old female with epilepsy developed dysphagia, dyspnea and impaired exercise 
tolerance. Obstruction caused by swollen lingual tonsil and edema in the epiglottis and arytenoid mucosa were 
found. Lingual tonsil and epiglottis biopsies displayed non-necrotizing granulomas. There was no evidence of viral, 
bacterial, mycobacterial or fungal infections. Chest X-ray, computerized tomography of chest and ultrasound of neck 
and abdomen remained unremarkable. Positron emission tomography/computed tomography (PET/CT) showed 
laryngeal enhancement. Empiric antimicrobials combined with prednisolone were insufficient to control her disease. 
In immunological evaluation, the patient had normal counts of B and T cells. Proportions of  CD27+ memory B cells 
(30.3%) and  IgD−IgM−CD27+ switched memory B cells (7.2%; normal range 6.5–29.2%) were normal. Percentage of 
activated  CD21low B cells was high (6.6%; normal range 0.6–3.5%). IgG (3.5 g/L; normal range 6.77–15.0 g/l) and all IgG 
subclass concentrations were low. Anti-polysaccharide responses were impaired, with 3/10 serotypes reaching a level 
of 0.35 µg/ml after immunization with  Pneumovax®. The findings were consistent with hypogammaglobulinemia 
resembling CVID, possibly secondary to antiepileptic medication. Her dyspnea and dysphagia responded favorably to 
subcutaneous IgG and rituximab.
Conclusions: Tonsillar granulomas can be the presenting and only clinical feature of B cell deficiency, highlighting 
the diversity of symptoms and findings in primary or secondary immunodeficiencies.
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Background
Tonsillar granulomatous inflammation is rare, most 
commonly caused by tuberculosis or sarcoidosis. 
Rarely, Hodgkin’s lymphoma, toxoplasmosis, fungal 
infection and squamous cell carcinoma are associated 
with pharyngeal granulomas [1, 2]. Granulomatous 
inflammation is frequently seen in common variable 
immunodeficiency (CVID), a heterogeneous immune 
defect characterized by aberrant B cell maturation, 
hypogammaglobulinemia, failure of specific antibody 
production, susceptibility to infections, and variable 
comorbidities [3–5]. Approximately 10–20% of CVID 
patients suffer from granulomatous inflammation, 
most commonly affecting lymph nodes and lungs [6, 7]. 
Differential diagnosis of secondary causes, such as drug 
induced mechanisms, must be considered whenever 
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CVID or B cell maturation defect is suspected. In 
addition, distinguishing granulomatous CVID from 
sarcoidosis remains challenging, as recently reviewed 
by Ameratunga et  al. [8]. Our patient presented with 
unusual granulomatous inflammation of the lingual tonsil 
and epiglottis causing dysphagia and airway obstruction; 
her condition shares features with primary and drug-
induced B cell deficiency as well as sarcoidosis.
Case presentation
A 29-years-old female experienced an episode of mild 
upper respiratory tract infection followed by a slowly 
developing dysphagia and dyspnea. This led to impaired 
exercise tolerance lasting several months, with recent 
subacute exacerbation. There was no significant history 
of travel or exposure to infectious agents. She had not 
suffered from fever or other acute or chronic infectious 
symptoms. Her palatine tonsils had been removed in 
childhood. She was diagnosed with epilepsy at age 
17 and had been free of epileptic symptoms for over 
5  years with levetiracetam (500  mg two times per day) 
and lamotrigine (150 mg two times per day). Her family 
history was unremarkable.
She spoke with hoarse voice, without signs or findings 
that would have suggested systemic involvement. 
There were no signs of generalized mucosal disease. 
Fiberoptic examination showed swelling of the lingual 
tonsil, epiglottic and arytenoid mucosa, causing airway 
obstruction (Fig.  1a). C-reactive protein concentration 
and blood sedimentation rate were low, and anti-
nuclear, anti-neutrophil, anti-glomerular basement 
membrane, anti-myeloperoxidase, anti-proteinase 3, 
tissue transglutaminase and cyclic citrullinated peptide 
antibodies were negative. Thyroid function was normal 
and thyroid peroxidase antibodies were 34 IU/ml (normal 
value < 60 IU/ml). Plasma parathyroid hormone (39 ng/l; 
Fig. 1 Fiberoptic findings in primary situation (a) and a modest improvement in edema and symptoms during prednisolone 60 mg/days treatment 
(b). Significant improvement in edema and symptoms 2 weeks after rituximab (c). Seven months after rituximab treatment, the patient was free of 
symptoms (d)
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normal 18–80 ng/l) and serum vitamin D-25 (77 nmol/l; 
normal > 50  nmol/l) were normal. No evidence for 
acute or chronic viral, bacterial, mycobacterial or 
fungal infections, including hepatitis B and C, human 
immunodeficiency virus and tularemia, was found.
Due to her swollen lingual tonsil and laryngeal mucosa 
causing airway obstruction, she was hospitalized 
and received empiric cefuroxime (1.5  g thrice daily) 
and methylprednisolone (75  mg once daily, height 
173  cm, weight 63  kg, prednisolone dose 1.2  mg/kg) 
intravenously. After a transient positive response, she 
was discharged from the hospital after 6  days. Soon 
after, she was readmitted to due to a rapid reoccurrence 
of the symptoms. A modest positive response was 
seen after per oral clindamycin and oral prednisolone 
(60  mg/days) with dose reduction for 14  days. Lingual 
tonsil and epiglottis were biopsied. Histology showed 
granulomatous reaction in lingual tonsil with  CD68+ 
(Kp-1) epithelioid histiocytes (Fig.  2). The  CD20+ B 
lymphocyte count was increased while Pax-5+ positive B 
lymphocyte count was normal.  CD138+ plasma cells were 
scarce, and they showed polytypic kappa- and lambda 
light chain expression. The number of  CD3+ T cells was 
normal, and most T cells were  CD4+. Eosinophils were 
practically absent and well-formed follicles were not 
seen. Epstein–Barr virus in  situ hybridization (EBER), 
p16, cytomegalovirus and mycobacteria were negative. 
Morphology, immunohistochemical staining, serum 
electrophoresis and bone marrow aspirate did not raise 
suspicion of lymphoid neoplasia, thus, no clonality 
studies were done.
Due to granulomas, sarcoidosis was considered. 
However, chest X-ray, computerized tomography of chest 
and ultrasound of neck and abdomen were unremarkable. 
Positron emission tomography/computed tomography 
(PET/CT) showed increased fluorodeoxyglucose 
(FDG) uptake in the lingual tonsil, without evidence of 
widespread sarcoidosis (Fig.  3). No other pathological 
FDG foci were found. Focal physiological FDG 
accumulation was seen in ureters on both sides of the 
spinal column. This is a common finding due to ureteral 
peristalsis and pooling of radiotracer in the recumbent 
patient. The patient had no neurological symptoms and 
brain magnetic resonance imaging was normal. Serum 
angiotensin converting enzyme (ACE) was within normal 
range (11–20 U/l; reference range 9–65 U/l) while daily 
urine calcium output was normal or slightly elevated 
(5.0–6.31 mmol; reference range 1.2–5.5 mmol).
Subsequently, an unusual presentation of primary or 
secondary immunodeficiency was considered. There was 
no consanguinity; the patient or her family had no history 
of repeated infections or autoimmunity. White cell, 
lymphocyte, and B, T and NK lymphocyte subset counts 
were within normal limits.  CD19+ B cell count was 
153 × 109/l (normal range 80–616 × 109/l). Proportions 
of memory  CD27+ B-cells (30.3%) and  IgD−IgM−CD27+ 
switched memory B cells 7.2%; (normal range 6.5–29.2%) 
were normal and the percentage of activated  CD21low B 
cells was high (6.6%; normal range 0.6–3.5%). Percentages 
of various  CD3+CD4+ and  CD3+CD8+ T cell subsets 
appeared normal. Serum total IgG (3.5 g/l; normal range 
6.77–15.0  g/l) and all IgG subclass concentrations were 
low: IgG1 2.45  g/l (normal range 4.9–11.4  g/l), IgG2 
0.91 g/l (normal range 1.5–6.4 g/l), IgG3 0.18 g/l (normal 
range 0.2–1.1 g/l) and IgG4 0.02 g/L (normal range 0.08–
1.4  g/l). Anti-polysaccharide response to  Pneumovax® 
were impaired, with only 3/10 serotypes reaching a 
level of 0.35 µg/ml after immunization. However, serum 
IgA (0.90  g/l; normal range 0.52–4.02  g/l) and IgM 
concentrations (0.57  g/l; normal range 0.47–2.84  g/l) 
were normal. Dihydrorhodamine test excluded chronic 
granulomatous disease. These findings were thus 
consistent with either granulomatous CVID or most 
likely secondary drug-induced hypogammaglobulinemia 
with a novel clinical presentation [3–5]. Genetic analysis 
(Blueprint Genetics, Primary Immunodeficiency Plus 
panel. https ://bluep rintg eneti cs.com/tests /panel s/
immun ology /prima ry-immun odefi cienc y-panel /) did not 
find known mutations causative of CVID-like or other 
primary immunodeficiencies.
Due to symptomatic upper airway obstruction, 
dysphagia, lack of evident infection and unsatisfactory 
response to prednisolone treatment and possible 
granulomatous CVID, the patient received 
immunoglobulin replacement and rituximab therapy 
 (Mabthera® 100  mg, 200  mg and 500  mg on three 
consecutive days combined with 100 mg hydrocortisone 
and 1  g paracetamol), with a favorable response within 
2  weeks accompanied by significant improvement in 
dysphagia and respiratory symptoms. Seven months 
later, her exercise capacity was good. She has remained 
asymptomatic for over 16  months after rituximab 
treatment. Her fiberoptic pharyngeal findings improved 
(Fig.  1). She continues to receive subcutaneous 
immunoglobulin replacement with serum IgG levels in 
the range of 10 to 12 g/l.
Discussion and conclusions
Our patient shares clinical and laboratory features 
with granulomatous CVID, with mild elevation in 
daily urine calcium. She lacks the most common and 
generally accepted sarcoidosis findings while plasma 
IgG levels and anti-polysaccharide antibody levels after 
 Pneumovax® were low [9–11]. Low IgG concentration 
and inability to respond to a vaccine combined with B 
cell depletion therapy in serious airway involvement 
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was thought to warrant IgG replacement. Although 
our patient’s condition resembles “possible CVID” 
[3–5], normal blood IgA and CD4 levels are not 
typical of granulomatous CVID [6, 7]. She had been on 
antiepileptic treatment without obvious side-effects for 
years. Clozapine, carbamazepine, phenytoin, lamotrigine 
and levetiracetam use may rarely be associated with the 
development of subsequent hypogammaglobulinemia 
[12–14]. Her condition may have developed secondary 
to antiepileptic treatment. These observations highlight 
the importance of potential drug-induced mechanisms in 
B-cell deficiencies.
Whether our patient suffers from a novel and 
unusual presentation of primary or secondary 
hypogammaglobulinemia remains to be determined. 
Though granulomatous lesions in CVID are common, 
to our knowledge tonsillar and epiglottic lesions have 
never been described. Good rituximab responses are 
commonly seen in CVID; limited rituximab experience 
in select sarcoidosis cases with poor response to 
primary medications has been reported. Based on our 
experience, we suggest that the diagnosis of primary or 
secondary immunological causes should be considered 
in tonsillar and/or epiglottic granulomas (Fig. 2).
Fig. 2 Histological findings (a, b) showing granulomatous reaction in lingual tonsil with CD68 (Kp-1) positive epitheloid histiocytes by 
immunohistochemistry (c). Strong CD20-immunopositivity in B-lymphocytes (d). Most CD3-positive (e) T-lymphocytes showed also CD4-positivity 
(f)
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Fig. 3 Positron emission tomography—computed tomography showed increased activity (arrows) in the lingual tonsil (a, b) without evidence of 
widespread sarcoidosis (c)
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